Login to Your Account

Spectrum Buys Out JV from Cell Therapeutics

By Trista Morrison

Tuesday, February 24, 2009
Less than three months after Spectrum Pharmaceuticals Inc. and Cell Therapeutics Inc. teamed up in a 50-50 joint venture to market the radioimmunotherapy drug Zevalin ([90Y]-ibritumomab tiuxetan), Spectrum is taking control of the compound. (BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription